Rhythm Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-02-01
- Employees
- 226
- Market Cap
- -
- Website
- http://www.rhythmtx.com
- Introduction
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 5966
- Registration Number
- NCT02849977
- Locations
- 🇺🇸
Axis Clinical Trails, Los Angeles, California, United States
🇺🇸PRI, LLC - Newport Beach - M3 Wake Research, Newport Beach, California, United States
🇺🇸South Florida Clinical Trials, Hialeah, Florida, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02431442
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02311673
- Locations
- 🇺🇸
Kansas University Medical Center, Kansas City, Kansas, United States
🇺🇸Winthrop University Hospital, Mineola, New York, United States
🇺🇸University of California Irvine, Irvine, California, United States
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT02041195
Effects of RM-493 on Energy Expenditure in Obese Individuals
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01867437
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT01749137